Ablynx NV (ABLX.BR)
6.97EUR
11:35am EDT
€0.06 (+0.87%)
€6.91
€6.95
€6.97
€6.84
68,996
106,957
€8.10
€2.78
About
Overall
| Beta: | 0.80 |
| Market Cap (Mil.): | €337.22 |
| Shares Outstanding (Mil.): | 48.80 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ABLX.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.65 | -- | -- |
| ROI: | -61.29 | -2.58 | 18.76 |
| ROE: | -63.10 | -2.66 | 19.59 |
BRIEF-Ablynx Q1 net loss EUR 6.7 million
BRUSSELS, May 15 - Ablynx NV : * Q1 net loss EUR 6.7 million * Net cash at end Q1 82.2 million EUR
BRIEF-Ablynx shares suspended pending fundraising result
BRUSSELS, Feb 28 - Ablynx NV : * Shares suspended pending results of fundraising - stock market regulator
BRIEF-Ablynx CEO sees partnering deals this year
BRUSSELS, Feb 27 - Ablynx NV : * CEO says during the coming year, expects important new partnering deals * Says net cash burn well controlled at just EUR21.1 million in 2012 * Says EUR62.8 million in cash at end of 2012
BRIEF-Ablynx enters into cancer deal with UK's Spirogen
BRUSSELS, Feb 25 - Ablynx NV : * Ablynx and Spirogen enter into a research collaboration to evaluate the
Ablynx books success with arthritis drug study
BRUSSELS - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.
Ablynx books success with arthritis drug study
BRUSSELS, Feb 13 - Belgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partnership deal with a bigger company.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

